arrow
Return

Workflow for E3 Ligase Ligand Validation for PROTAC Development

delete2025-02-11
delete0
delete
OA
AI
N
Nebojša Miletić
J
Janik Weckesser
T
Thorsten Mosler
R
Rajeshwari Rathore
M
Marina E. Hoffmann
P
Paul Gehrtz
S
Sarah Schlesiger
I
Ingo V. Hartung
N
Nicola Berner
S
Stephanie Wilhelm
J
Juliane Müller
B
Bikash Adhikari
V
Václav Němec
S
Saran Aswathaman Sivashanmugam
L
Lewis Elson
H
H. Holzmann
M
Martin P. Schwalm
L
Lasse Hoffmann
K
Kamal R. Abdul Azeez
S
Susanne Müller
B
Bernhard Küster
E
Elmar Wolf
I
Ivan Đikić
S
Stefan Knapp *
DOI:10.1021/acschembio.4c00812delete
deleteOriginal
deleteShare
deleteSave
View PDF
Abstract

Abstract

En 中文
Proteolysis targeting chimeras (PROTACs) have gained considerable attention as a new modality in drug discovery. The development of PROTACs has been mainly focused on using CRBN (Cereblon) and VHL (Von Hippel-Lindau ligase) E3 ligase ligands. However, the considerable size of the human E3 ligase family, newly developed E3 ligase ligands, and the favorable druggability of some E3 ligase families hold the promise that novel degraders with unique pharmacological properties will be designed in the future using this large E3 ligase space. Here, we developed a workflow aiming to improve and streamline the evaluation of E3 ligase ligand efficiency for PROTAC development and the assessment of the corresponding degradable target space using broad-spectrum kinase inhibitors and the well-established VHL ligand VH032 as a validation system. Our study revealed VH032 linker attachment points that are highly efficient for kinase degradation as well as some of the pitfalls when using protein degradation as a readout. For instance, cytotoxicity was identified as a major mechanism leading to PROTAC- and VHL-independent kinase degradation. The combination of E3 ligase ligand negative controls, competition by kinase parent compounds, and neddylation and proteasome inhibitors was essential to distinguish between VHL-dependent and -independent kinase degradation events. We share here the findings and limitations of our study and hope that this study will provide guidance for future evaluations of new E3 ligase ligand systems for degrader development.
Keywords:
PROTEIN-DEGRADATION
KINASE INHIBITORS
SMALL MOLECULES
DISCOVERY
UBIQUITINATION
RESISTANCE
DEGRADERS
RECEPTOR
DESIGN
ABL
AI Summary

AI Summary

Key information extracted from the uploaded paper, including a brief overview, abstract, background, key highlights, visual analysis, and future outlook.

Journal

ACS Chemical Biology cover
ACS Chemical Biology
IF:
3.8
Papers:
5.4K
Citations:
1.7W

Organization

G
Goethe University Frankfurt
Scholars:
2.6W
Papers: 2.0W
Citations: 3.0W
G
German Cancer Research Center (DKFZ)
Scholars:
1.5W
Papers: 1.1W
Citations: 17
H
Helmholtz Association
Scholars:
13.2W
Papers: 10.7W
Citations: 145
T
Technical University of Munich
Scholars:
5.2W
Papers: 3.9W
Citations: 6.2W
researcher View more organizations